ERBB2 and breast carcinoma: Similarly, Bozepinib, an anti-tumor medication, also targets the HER2/ERK pathway, as can be evidenced on Western blot through the complete inhibition of phosphorylated HER2 following treatment with 5 μM of Bozepinib after 2 h on breast cancer cells [79].